Vuno Inc.

Equities

A338220

KR7338220007

IT Services & Consulting

End-of-day quote Korea S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
28,300 KRW +1.43% Intraday chart for Vuno Inc. +8.43% -32.62%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Vuno Inc. announced that it has received KRW 10.4 billion in funding CI
Vuno Inc. announced that it expects to receive KRW 10.4 billion in funding CI
Vuno Inc. Secures FDA 510(K) Clearance for Vuno Med-Deepbrain CI
Vuno Secures US FDA Approval for AI-Based Brain Imaging Analysis Medical Device MT
An unknown buyer agreed to acquire 2.94% stake in Puzzle AI Co., Ltd. for KRW 2.5 billion. CI
VUNO Inc.'s First AI-Based Prospective Study Results Published in Critical Care CI
Vuno Inc.(KOSDAQ:A338220) added to S&P Global BMI Index CI
Vuno Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Vuno Inc. announced that it has received KRW 9.999978514 billion in funding CI
Vuno Inc. announced that it expects to receive KRW 9.999978514 billion in funding CI
Vuno Inc. announced that it has received KRW 5 billion in funding CI
Vuno Inc. announced that it expects to receive KRW 5 billion in funding CI
Vuno Inc.(KOSDAQ:A338220) dropped from S&P Global BMI Index CI
3,818,929 Common Stock of Vuno Inc. are subject to a Lock-Up Agreement Ending on 26-FEB-2022. CI
Korean Ministry of Food and Drug Safety Designates the VUNO Inc.'s Artificial Intelligence-Based Electrocardiogram Analysis Software Vuno Med?-Deepecg? as the Ministry's 16th Breakthrough Device CI
VUNO Inc. Signs Another Deal with Samsung Electronics to Incorporate AI-Assisted Solutions into Samsung's Premium Ceiling Type Digital Radiography System CI
Vuno Inc.(KOSDAQ:A338220) added to S&P Global BMI Index CI
738,000 Common Stock of Vuno Inc. are subject to a Lock-Up Agreement Ending on 27-AUG-2021. CI
Vuno Inc. Received Regulatory Approval from the Ministry of Food and Drug Safety for its VUNO Med®–DeepCARS™ CI
VUNO Inks Deal with Samsung Electronics to Embed AI-powered Algorithms in Samsung's Premium Mobile X-ray System CI
54,000 Common Stock of Vuno Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2021. CI
3,818,929 Common Stock of Vuno Inc. are subject to a Lock-Up Agreement Ending on 29-MAR-2021. CI
Vuno Inc. has completed an IPO in the amount of KRW 37.8 billion. CI
Vuno Inc. has filed an IPO. CI
Vuno Inc. announced that it has received KRW 3 billion in funding from DongKoo Bio&Pharma Co., Ltd. CI
Chart Vuno Inc.
More charts
Vuno Inc is a Korea-based company primarily engaged in the development of medical diagnostic, predictive technologies and solutions based on artificial intelligence (AI) technology.The Company develops and manufactures medical imaging products that assist with medical image-based diagnosis such as X-ray, computed tomography (CT), magnetic resonance imaging (MRI), and funduscopy; pathology products that assist in the detection of digital scanners, microscopy-based cell quantification and tumor cells; biosignal products that assist and predict diagnosis based on time-series biosignal data such as vital signs and electrocardiogram; medical voice products that automatically create medical charts based on voice recognition. In addition, the Company sells an embolic material product, Nexpear. The Company sells its products in domestic and overseas markets such as Japan, Europe, and the United States.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
28,300 KRW
Average target price
45,000 KRW
Spread / Average Target
+59.01%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. A338220 Stock
  4. News Vuno Inc.
  5. Vuno Secures US FDA Approval for AI-Based Brain Imaging Analysis Medical Device